MYTSYK, Yulian, Victor DOSENKO, Yuriy BORYS, Askold KUCHER, Katarina GAZDIKOVA, Dietrich BUSSELBERG, Martin CAPRNDA, Peter KRUŽLIAK, Ammad Ahmad FAROOQI and Manyuk LUBOV. MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma. Online. International Urology and Nephrology. Dordrecht: Springer, 2018, vol. 50, No 5, p. 851-859. ISSN 0301-1623. Available from: https://dx.doi.org/10.1007/s11255-018-1841-x. [citováno 2024-04-23]
Other formats:   BibTeX LaTeX RIS
Basic information
Original name MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma
Authors MYTSYK, Yulian (804 Ukraine), Victor DOSENKO (804 Ukraine), Yuriy BORYS (804 Ukraine), Askold KUCHER (804 Ukraine), Katarina GAZDIKOVA (703 Slovakia), Dietrich BUSSELBERG (634 Qatar), Martin CAPRNDA (703 Slovakia), Peter KRUŽLIAK (703 Slovakia, guarantor, belonging to the institution), Ammad Ahmad FAROOQI (586 Pakistan) and Manyuk LUBOV (804 Ukraine)
Edition International Urology and Nephrology, Dordrecht, Springer, 2018, 0301-1623.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30217 Urology and nephrology
Country of publisher Netherlands
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.596
RIV identification code RIV/00216224:14110/18:00102916
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1007/s11255-018-1841-x
UT WoS 000431429000008
Keywords in English Renal cell carcinoma; MiRNA-15a; Biomarker; Diagnosis; Molecular marker
Tags 14110121, EL OK, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 10/2/2019 16:07.
Abstract
Currently, there is no accurate diagnostic molecular biomarker for renal cell carcinoma (RCC). The aim of this study was to assess the expression of microRNA-15a (miR-15a) in urine of patients with RCC and to evaluate its potential as a diagnostic molecular biomarker. In total, 67 patients with solid renal tumors were enrolled: clear-cell RCC (ccRCC, n = 22), papillary RCC (pRCC, n = 16), chromophobe RCC (chRCC, n = 14), oncocytoma (n = 8), papillary adenoma (n = 2) and angiomyolipoma (n = 5). MiRNA-15a expression levels measurement in urine were performed using qPCR. Urine of 15 healthy volunteers without kidney pathology was used as control. We observed a difference in mean miR-15a expression values in groups of pre-operative patients with RCC, benign renal tumors and healthy persons (2.50E-01 +/- 2.72E-01 vs 1.32E-03 +/- 3.90E-03 vs 3.36E-07 +/- 1.04E-07 RFU, respectively, p < 0.01). There was no difference in miR-15a expression between ccRCC, pRCC and chRCC (p > 0.05). Direct association between RCC size and miR-15a expression values was obtained (Pearson correlation coefficient-0.873). On the 8th day after nephrectomy, mean expression value in patients with RCC decreased by 99.53% (p < 0.01). MiR-15a expression differentiated RCC from benign renal tumors with 98.1% specificity, 100% sensitivity at a cut-off value of 5.00E-06 RFU, with AUC-0.955. MiR-15a expression measured in urine may be used as diagnostic molecular biomarker for RCC.
PrintDisplayed: 23/4/2024 23:15